Estudo citogenético e pesquisa de mutações nos genes JAK2 e MPL em Policitemia vera, Mielofibrose primária e Trombocitemia essencial

• Ano de defesa: 2010
• Autor(a) principal: Santos, Leonardo Caires dos [UNIFESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
• Palavras-chave em Português: Citogenética; JAK2 V617F; MPL W515K/L; Mutações no éxon 12 do JAK2; Neoplasias mieloproliferativas; Doenças mieloproliferativas-mielodisplásicas
• Link de acesso: http://repositorio.unifesp.br/handle/11600/9496

Introcuction: Polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF) are clonal disorders of hematopoietic stem cell and clinical and biological aspects have in common that hinder their diagnosis, however, cytogenetic and molecular studies represent important tools to assist in this procedure. Therefore, the investigation of the presence of JAK2 V617F, mutations in exon 12 of JAK2, MPL W515K of MPLW515L and cytogenetic alterations per karyotype and FISH can provide a more detailed view for the diagnosis and prognosis of these diseases. In this study such cytogenetic and molecular changes were correlated with degree of fibrosis in cases of MF, the number of leukocytes, platelets, hemoglobin and age at diagnosis in PV, ET and MF Method: The karyotype by G-band was performed on samples of bone marrow, grown in culture for short duration (24h) without mitogens and processed as usual (Chauffaille, 2006). The sample (1 ml) was intended to FISH with probes for the regions: 20q12, 20q13.12, 13q14.3, 13qter, 8p11.1-q11.1 and 9q12. The investigation of JAK2 V617F and MPL W515K/L mutations was performed on DNA from peripheral blood by real time PCR, using the kit MutaScreenTM JAK2 (IPSOGEN). The search for mutations in exon 12 of JAK2 was performed by direct sequencing. Results: Chromosomal abnormalities were observed in 11.8% of PV, 17.6% of MF and none of the ET, no relation between clinical data and assessed chromosomal alterations. Chromosomal abnormalities were not amplified by FISH. JAK2 V617F was observed in 90% of PV, 42.8% of MF and 47% of ET. Patients with JAK2 V617F negative PV showed lower levels of platelets in relation to V617F positive PV (p <0.0001). MF V617F negative and MPL W515L positive showed higher degrees of fibrosis than V617F negative (p =0.003). Was not detected the presence of mutations in exon 12 of JAK2 in PV patients. MPL W515L was observed in a case of MF and a TE. No MPL W515K mutation was found in patients with ET and MF. The ET patient MPL W515L positive showed no clinical different from other patients with ET, whereas the patient with MF MPL W515L showed positive clinical more aggressive when compared to other patients with MF. The number of clonal abnormalities showed no difference in the clinical data evaluated. Conclusions: Different types of clonal abnormalities in myeloproliferative neoplasms exalt their different pathophysiological mechanism, aiding in the diagnosis and understanding of the biology of these diseases. This study allowed the cytogenetics and molecular characterization of PV, MF and ET.